A population-based study of gefitinib in patients with non-small cell lung cancer.
Survival data for non-small cell lung cancer is typically reported from clinical trials that include patients fit enough to meet treatment criteria. The denominator of all patients from which the gefitinib-treated population is derived has rarely been reported and the impact of gefitinib on population-based outcomes is difficult to measure. We have retrospectively reviewed data of 626 patients who received gefitinib in Ibaraki Prefecture (with a population of 3 million) in Japan from July 2002 until September 2007. Overall response rate was found to 30.8%, and the median survival time was 8.0 months (95% confidence interval: 7.0-9.0 months). Female gender, good PS, and adenocarcinoma were significantly associated with prolonged survival. Adverse events were generally mild and were mostly skin reactions and diarrhea. Our population-based study has generated similar results to those previously reported in published clinical trials, which had restrictive criteria for eligible patients.
Hayashibara
Kenji
K
Ibaraki Higashi Hospital, Ibaraki, Japan.
Satoh
Hiroaki
H
Shinohara
Yoko
Y
Inagaki
Masaharu
M
Kaburagi
Takayuki
T
Hashimoto
Toshio
T
Kurishima
Koichi
K
Ishikawa
Hiroichi
H
Ichimura
Hideo
H
Nawa
Takeshi
T
Funayama
Yasunori
Y
Matsumura
Takeshi
T
Kagohashi
Katsunori
K
Endo
Takeshi
T
Furukawa
Kinya
K
Kishi
Koji
K
Sumi
Masaaki
M
Kamiyama
Koichi
K
Ishikawa
Shigemi
S
D000230:Adenocarcinoma / Q000188:drug therapy; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D018287:Carcinoma, Large Cell / Q000188:drug therapy; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy* / Q000401:mortality; D002294:Carcinoma, Squamous Cell / Q000188:drug therapy; D003710:Demography; D005260:Female; D000077156:Gefitinib; D006801:Humans; D007564:Japan / Q000453:epidemiology; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000401:mortality; D008297:Male; D008875:Middle Aged; D011799:Quinazolines / Q000009:adverse effects / Q000627:therapeutic use*; D012907:Smoking / Q000453:epidemiology
D000970:Antineoplastic Agents; D011799:Quinazolines; D000077156:Gefitinib